Monoclonal antibodies which specifically bind to human immune interferon

• US 4,599,306 A
• Filed: 04/15/1983
• Issued: 07/08/1986
• Est. Priority Date: 04/15/1983
• Status: Expired due to Term

• Current Assignee: Amgen Inc.
• Original Assignee: Amgen Inc.
• Inventors: Altrock, Bruce W.
• Primary Examiner(s): Wiseman, Thomas G.
• Assistant Examiner(s): Moskowitz, M.
• Application Number:
  US06/485,205
• Time in Patent Office: 1,180 Days
• Field of Search: 435/4, 435/7, 435/68, 435/811, 435/948, 435/172.2, 435/70, 435/172, 435/240, 436/547, 436/548, 436/804, 436/518, 436/536, 260/112 R, 935/104, 935/108, 935/110
• US Class Current: 435/7.93
• CPC Class Codes: C07K 14/57 IFN-gamma
• CPC Class Codes: C07K 16/249 Interferons
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: Y10S 930/142 Interferon

Abstract

Disclosed are monoclonal antibody substances specifically immunologically reactive with native and recombinant human immune interferon ("IFN-γ") and with polypeptides having amino acid sequences substantially duplicative of sequences extant in IFN-γ. In a presently preferred embodiment, antibody substances are produced by new mouse-mouse hybridoma tumor cell line A.T.C.C. HB 8291 and are immunoreactive with native IFN-γ, with recombinant IFN-γ and polypeptide analogs thereof, and with a nonadecapeptide whose amino acid sequence duplicates that of the final nineteen amino acid residues of the carboxyl terminal of IFN-γ. These preferred antibody substances, while displaying high affinity for IFN-γ, do not neutralize antiviral biological activity of the interferon. They are usefully employed in the detection, quantification and affinity purification of IFN-γ and IFN-γ analogs as well as in investigations relating to the mode of biological action of IFN-γ.

Claims

1. As a new composition, a murine-derived hybridoma cell line ATCC HB8291 capable of producing in the medium of its growth an IgG monoclonal antibody capable of specifically binding to human IFN-γ

in an antigen-antibody complex.

2. As a new composition, the monoclonal antibody produced from hybridoma cell line ATCC HB8291, said antibody capable of specifically binding to human IFN-γ

.

3. In an immunological procedure for isolation of biologically active human IFN-γ

or polypeptide analogs thereof from a biological fluid comprising the steps of contacting IFN-γ

or polypeptide analogs thereof with an antibody specific for IFN-γ

for a time and under conditions sufficient for formation of an immune complex of said IFN-γ

or polypeptide analogs thereof and said antibody specific for IFN-γ and

isolating said IFN-γ

or polypeptide analogs thereof from said immune complex, the improvement comprising;

employing as said specific antibody an IgG monoclonal antibody produced by a murine-derived hybridoma cell line deposited as ATCC No. HB8291, said antibody capable of specifically binding to human IFN-γ

in an antigen-antibody complex.

4. In an immunological procedure for the quantitative detection of IFN-γ

or a polypeptide analog thereof, from a biological fluid comprising the steps of contacting IFN-γ

or polypeptide analogs thereof with an antibody specific for IFN-γ

for a time and under conditions sufficient for formation of an immune complex of said IFN-γ

or polypeptide analogs thereof and said antibody specific for IFN-γ and

detecting the presence of said immune complex, the improvement comprising;

employing as said specific antibody of IgG monoclonal antibody produced by a murine-derived hybridoma cell line deposited as ATCC No. HB8291, said antibody capable of specifically binding to human IFN-γ

in an antigen-antibody complex.